| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| chr-3996 | histone deacetylase 1 | NA | Successful target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] Lymphoma[MeSHID:D008223] |
0.64 | phase 1/2 | inhibitor |
| chr-3996 | histone deacetylase 1 | NA | Successful target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] Lymphoma[MeSHID:D008223] |
0.64 | phase 1/2 | unknown |
| chr-3996 | histone deacetylase 2 | NA | Clinical trial target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] Lymphoma[MeSHID:D008223] |
0.74 | phase 1/2 | unknown |
| chr-3996 | histone deacetylase 2 | NA | Clinical trial target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] Lymphoma[MeSHID:D008223] |
0.74 | phase 1/2 | inhibitor |
| chr-3996 | histone deacetylase 3 | NA | Clinical trial target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] Lymphoma[MeSHID:D008223] |
0.76 | phase 1/2 | inhibitor |
| chr-3996 | histone deacetylase 3 | NA | Clinical trial target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] Lymphoma[MeSHID:D008223] |
0.76 | phase 1/2 | unknown |
| click here to return to the previous page | ||||||||